Logo image of ROIV

ROIVANT SCIENCES LTD (ROIV) Stock Fundamental Analysis

NASDAQ:ROIV - Nasdaq - BMG762791017 - Common Stock - Currency: USD

11.58  -0.04 (-0.34%)

After market: 11.5102 -0.07 (-0.6%)

Fundamental Rating

4

Taking everything into account, ROIV scores 4 out of 10 in our fundamental rating. ROIV was compared to 566 industry peers in the Biotechnology industry. ROIV has a great financial health rating, but its profitability evaluates not so good. ROIV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ROIV has reported negative net income.
In the past year ROIV has reported a negative cash flow from operations.
In multiple years ROIV reported negative net income over the last 5 years.
In the past 5 years ROIV always reported negative operating cash flow.
ROIV Yearly Net Income VS EBIT VS OCF VS FCFROIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 1B -1B 2B 3B 4B

1.2 Ratios

ROIV has a better Return On Assets (-2.01%) than 89.75% of its industry peers.
Looking at the Return On Equity, with a value of -2.25%, ROIV belongs to the top of the industry, outperforming 90.99% of the companies in the same industry.
Industry RankSector Rank
ROA -2.01%
ROE -2.25%
ROIC N/A
ROA(3y)-4.9%
ROA(5y)-0.13%
ROE(3y)-21.77%
ROE(5y)-11.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROIV Yearly ROA, ROE, ROICROIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

ROIV's Gross Margin of 89.85% is amongst the best of the industry. ROIV outperforms 91.17% of its industry peers.
ROIV's Gross Margin has been stable in the last couple of years.
ROIV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.41%
GM growth 5YN/A
ROIV Yearly Profit, Operating, Gross MarginsROIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 2K -2K -4K

More info and screens

8

2. Health

2.1 Basic Checks

ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
ROIV has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ROIV has an improved debt to assets ratio.
ROIV Yearly Shares OutstandingROIV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 200M 400M 600M 800M
ROIV Yearly Total Debt VS Total AssetsROIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

ROIV has an Altman-Z score of 8.83. This indicates that ROIV is financially healthy and has little risk of bankruptcy at the moment.
ROIV's Altman-Z score of 8.83 is amongst the best of the industry. ROIV outperforms 86.75% of its industry peers.
ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.83
ROIC/WACCN/A
WACC8.92%
ROIV Yearly LT Debt VS Equity VS FCFROIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

A Current Ratio of 37.91 indicates that ROIV has no problem at all paying its short term obligations.
The Current ratio of ROIV (37.91) is better than 99.29% of its industry peers.
ROIV has a Quick Ratio of 37.91. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ROIV (37.91) is better than 99.29% of its industry peers.
Industry RankSector Rank
Current Ratio 37.91
Quick Ratio 37.91
ROIV Yearly Current Assets VS Current LiabilitesROIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.28% over the past year.
Looking at the last year, ROIV shows a very negative growth in Revenue. The Revenue has decreased by -59.09% in the last year.
ROIV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 73.73% yearly.
EPS 1Y (TTM)88.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%176.67%
Revenue 1Y (TTM)-59.09%
Revenue growth 3Y73.73%
Revenue growth 5YN/A
Sales Q2Q%-75.74%

3.2 Future

Based on estimates for the next years, ROIV will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.79% on average per year.
ROIV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 58.64% yearly.
EPS Next Y71.62%
EPS Next 2Y-0.36%
EPS Next 3Y-4.72%
EPS Next 5Y18.79%
Revenue Next Year-34.63%
Revenue Next 2Y-55.68%
Revenue Next 3Y-22.27%
Revenue Next 5Y58.64%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ROIV Yearly Revenue VS EstimatesROIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
ROIV Yearly EPS VS EstimatesROIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ROIV. In the last year negative earnings were reported.
Also next year ROIV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ROIV Price Earnings VS Forward Price EarningsROIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ROIV Per share dataROIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

ROIV's earnings are expected to decrease with -4.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.36%
EPS Next 3Y-4.72%

More info and screens

0

5. Dividend

5.1 Amount

ROIV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROIVANT SCIENCES LTD

NASDAQ:ROIV (5/1/2025, 6:08:33 PM)

After market: 11.5102 -0.07 (-0.6%)

11.58

-0.04 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2025-02-10/bmo
Earnings (Next)N/A N/A
Inst Owners69.81%
Inst Owner ChangeN/A
Ins Owners7.28%
Ins Owner Change-8.69%
Market Cap8.26B
Analysts85
Price Target17.19 (48.45%)
Short Float %11.54%
Short Ratio7.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)80.76%
Min EPS beat(2)-18.6%
Max EPS beat(2)180.12%
EPS beat(4)3
Avg EPS beat(4)86.34%
Min EPS beat(4)-18.6%
Max EPS beat(4)180.12%
EPS beat(8)5
Avg EPS beat(8)43.36%
EPS beat(12)7
Avg EPS beat(12)24.66%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-67.92%
Min Revenue beat(2)-91.09%
Max Revenue beat(2)-44.75%
Revenue beat(4)1
Avg Revenue beat(4)-18.56%
Min Revenue beat(4)-91.09%
Max Revenue beat(4)71.59%
Revenue beat(8)4
Avg Revenue beat(8)-2.03%
Revenue beat(12)6
Avg Revenue beat(12)0.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.91%
EPS NY rev (1m)0%
EPS NY rev (3m)51.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)38.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 163.9
P/FCF N/A
P/OCF N/A
P/B 1.59
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS0.07
BVpS7.27
TBVpS7.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.01%
ROE -2.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.85%
FCFM N/A
ROA(3y)-4.9%
ROA(5y)-0.13%
ROE(3y)-21.77%
ROE(5y)-11.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.41%
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.15%
Cap/Sales 8.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 37.91
Quick Ratio 37.91
Altman-Z 8.83
F-Score4
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%176.67%
EPS Next Y71.62%
EPS Next 2Y-0.36%
EPS Next 3Y-4.72%
EPS Next 5Y18.79%
Revenue 1Y (TTM)-59.09%
Revenue growth 3Y73.73%
Revenue growth 5YN/A
Sales Q2Q%-75.74%
Revenue Next Year-34.63%
Revenue Next 2Y-55.68%
Revenue Next 3Y-22.27%
Revenue Next 5Y58.64%
EBIT growth 1Y-1.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-557.22%
EBIT Next 3Y-105.53%
EBIT Next 5YN/A
FCF growth 1Y5.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.48%
OCF growth 3YN/A
OCF growth 5YN/A